Navina, a New York-based AI-powered clinical intelligence platform provider, has raised $55 million in Series C funding, bringing its total funding to $100 million.
Investors
The round was led by Growth Equity at Goldman Sachs Alternatives, with participation from existing investors, including Vertex Ventures Israel, Grove Ventures, and ALIVE.
Goldman Sachs is a global investor in alternatives, managing over $500 billion in assets. It invests across private equity, private credit, real estate, infrastructure, sustainability, and hedge funds. Since 2003, Growth Equity at Goldman Sachs Alternatives has invested over $13 billion in companies, focusing on growth-stage and technology-driven businesses spanning multiple industries, including enterprise technology, financial technology, consumer, and healthcare.
Navina Use of Funds
The company will use the funding to fuel its expansion across the U.S. healthcare market, enhance its AI technology, and further drive improvements in patient outcomes by bringing proactive clinical intelligence to every outpatient interaction.
About Navina
Navina is a digital health SaaS company that provides an AI-powered clinical intelligence platform to help primary care providers convert unstructured and fragmented patient data into actionable insights. Its AI copilot is designed to help healthcare providers quickly interpret patient data, streamline workflows, and enhance decision-making. Navina supports over 10,000 healthcare professionals and has formed strategic partnerships with major healthcare organizations, including agilon health, InnovaCare Health, Millennium Physician Group, and Privia Health.
Funding Details
Company: Navina
Raised: $55.0M
Round: Series C
Funding Date: March 2025
Lead Investor: Growth Equity at Goldman Sachs Alternatives
Additional Investors: Vertex Ventures Israel, Grove Ventures, ALIVE
Company Website: https://www.navina.ai/
Software Category: Healthcare AI & Clinical Decision Support
Source: https://www.navina.ai/news/navina-secures-55m-series-c-funding-led-by-growth-equity-at-goldman-sachs-alternatives